Last reviewed · How we verify
NCT06551818
A Clinical Study to Assess Safety, Efficacy and In-use Tolerability of Different Dosages of Hair Growth Products in Patients With Mild to Moderate Androgenic Alopecia (Grade I to III).
NA trial testing SesZen-Bio Low Dose 1 (350 mg extract) in Androgenic Alopecia in 72 participants. Not yet recruiting.
2 March 2025
Quick facts
| Lead sponsor | NovoBliss Research Pvt Ltd |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | other |
| Enrollment | 72 |
| Start date | 30 August 2024 |
| Primary completion | 2 March 2025 |
| Estimated completion | 2 March 2025 |
Drugs / interventions tested
- SesZen-Bio Low Dose 1 (350 mg extract)
- SesZen-Bio Low Dose 1 (150 mg liposomal)
- SesZen-Bio High Dose 1 (500 mg extract)
- Placebo
Conditions studied
- Androgenic Alopecia — all drugs for Androgenic Alopecia →
Sponsor
NovoBliss Research Pvt Ltd — full company profile →
Who can join
Adults 25 to 45, any sex, with Androgenic Alopecia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, interventional, exploratory, four-arm - dose response study, comparative, double-blind, randomized, placebo-control, proof of concept, safety, efficacy and in-use tolerability study of three different dosage formulation of test hair growth products and placebo in patients with mild to moderate Androgenic Alopecia (Grade I to III).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Nanotechnology-Based Strategies for Hair Regeneration: Mechanistic Insights and Translational Perspectives for Androgenetic Alopecia.
Zhou W, Han R. · · 2026 · PMID 41898168 · DOI 10.3390/biomedicines14030521
Verify or expand the search:
- PubMed search for NCT06551818
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Androgenic Alopecia
Currently open trials in the same condition.
- NCT07373054 — Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia · NA · recruiting
- NCT07107841 — Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site) · NA · recruiting
- NCT07203599 — A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes · Phase 1, PHASE2 · recruiting
- NCT06697080 — Umbilical Cord-derived Mesenchymal Stem Cell Exosomes on Hair Growth in Patients With Androgenetic Alopecia · NA · active not recruiting
- NCT05938569 — Computer-Assisted Hair Restoration Study Using ARTAS System · NA · recruiting
Other NovoBliss Research Pvt Ltd trials
Trials by the same sponsor.
- NCT07466667 — To Determine the Effect of Phaseolean on Glycemic Response to Carbohydrate Rich Meal in Healthy Adult Human Participants · NA · not yet recruiting
- NCT07423325 — Validation of Skin Instrumentation to Detect Ceramide-Driven Lipid Replenishment - Assessing Skin Glow, Hydration, Trans · NA · not yet recruiting
- NCT07333300 — Exploratory Clinical Investigation on Neurosensory Responses Via EEG Headband in Adults With Mild to Moderate Atopic Der · NA · not yet recruiting
- NCT07324759 — Clinical Study to Assess Safety, Effectiveness and In-Use Tolerability of Saffron Extract Capsules for Improving Skin He · NA · not yet recruiting
- NCT07195487 — A Clinical Study to Evaluate the Safety, Effectiveness and In-Use Tolerability of Hair Growth and Scalp Health Serum in · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06551818 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NovoBliss Research Pvt Ltd
- Last refreshed: 13 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06551818.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing